What are your takeaways from the GPRC5D-Targeted CAR-T trial (Mailankody et al. NEJM Sept 2022) and any key differences compared to the BCMA directed products?

Topics: Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question

Answer from: Medical Oncologist at Academic Institution

I think it is hard to draw too many conclusions given that this is a first in human phase I study with only a small number of patients. What is promising here is that GPRC5D seems to be a good target for myeloma, even among patients with prior exposure to BCMA-targeted therapy. The population in thi...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Agree with @Ben Derman on all fronts! The one othe...

Related Questions